Helix Nanotechnologies

Helix Nanotechnologies (HelixNano) is a Boston-based biotechnology company developing what it describes as a next-generation mRNA platform intended to address cancer, COVID-19 and climate-related problems. The company frames mRNA as a programmable interface to biology, with the goal of making treatments inexpensive and development decentralized so that biological function can be modified in a targeted, rapid fashion. It states that by approaching mRNA improvements from first principles it has compressed experiments that previously required months or years into weeks, at costs measured in thousands rather than millions of dollars.

The company has begun applying this technology in two disclosed directions: moving a COVID-19 vaccine candidate aimed at immunocompromised patients toward the clinic, and testing an intervention described as having large environmental impact. Co-founder Hannu Rajaniemi characterizes the longer-term aim as building a unified interface to the immune system — reading information from the immune system and writing instructions back to it — with an illustrative milestone being large-scale cancer prevention trials that keep early-stage disease from progressing to advanced tumors.

Helix Nanotechnologies is categorized across artificial intelligence, biotech, genomics and nanotechnology, and reported a team size of 22.

Founding story

The company was co-founded by Hannu Rajaniemi, a Finnish-American science fiction author who holds a PhD in string theory from the University of Edinburgh and previously co-founded a company with another string theorist that solved mathematical problems for industry with a team of around ten PhDs. Nikolai Eroshenko is listed as founder and Chief Scientific Officer.

Traction

Publicly described progress includes advancing a COVID-19 vaccine candidate for immunocompromised patients toward the clinic and testing an intervention intended to have significant environmental impact. The company reported a team of 22 people.

Latest developments

In April 2024, co-founder Hannu Rajaniemi discussed the company's work on a podcast, describing the platform as a unified interface to the immune system and outlining a five-year goal of demonstrating closed-loop interaction with the immune system, illustrated by a hypothetical 100,000-patient cancer prevention trial.